Controversy surrounded Hims & Hers’ commercial, called ‘Sick of the System’, in the lead up to America’s biggest sporting ...

A TV commercial that the telehealth company Hims & Hers Health (NYSE:HIMS) is planning to run during the upcoming Super Bowl LIX coverage to promote its compounded weight loss products has drawn ...

Exclusive: ASA calls number of parallel probes ‘significant’ and describes tackling issue as ‘priority’ after it issued ...

Hims & Hers stock price continues to fire on all cylinders this year and is hovering near its highest level on record. It has ...

Telehealth company Hims & Hers stirred up controversy by debuting a 2025 Super Bowl ad touting the benefits of its ...

Novo Nordisk called out suppliers of compounded weight loss drugs following Hims & Hers’ controversial Super Bowl ad.

The next FDA Commissioner could solve two big problems with one powerful policy: encourage independent testing of both ...

Ozempic and Wegovy maker Novo Nordisk placed a print ad responding to the Super Bowl spot from competitor Hims & Hers.

Drug industry calls out telehealth company Hims & Hers' Super Bowl ad touting its knock-off weight loss medications.

In this video, I will go over Novo Nordisk's (NVO-3.62%) and Eli Lilly's recent earnings report. Watch the short video to learn more, consider subscribing, and click the special offer link below.

In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO) stands against the other stocks. Ken Fisher is the founder and executive chairman of Fisher Asset Management ...

Telehealth company Hims & Hers is pushing the boundaries of drug compounding and testing the limits of regulators.